NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, affects the central nervous system to produce peripheral hyperglycemia in conscious rats. 1997

K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.

To determine whether the nitric oxide (NO) system in the central nervous system (CNS) is involved in the peripheral metabolism of carbohydrate we injected NG-methyl-L-arginine (L-NMA), an inhibitor of NO synthase, into the third cerebral ventricle of unanesthetized, unrestrained rats and determined the plasma level of glucose. This intracerebroventricular (i.c.v.) injection of the drug increased the plasma level of glucose dose-dependently, whereas an intravenous (i.v.) injection had no effect. The hyperglycemia thus induced was suppressed by concomitant i.c.v. or prior i.v. administration of L-arginine. Concomitant administration of D-arginine did not affect hyperglycemia by L-NMA. The i.c.v. injection of 5 x 10(-6) mol L-NMA increased plasma levels of glucose, epinephrine and norepinephrine, and serum levels of glucagon. However, plasma levels of insulin were unchanged, despite the presence of hyperglycemia. The hyperglycemia produced by L-NMA was completely inhibited by bilateral adrenalectomy. It was also inhibited by prior intraperitoneal injection of phentolamine, but not of propranolol or naloxone. Results suggest that L-NMA acts on the CNS to stimulate adrenal secretion of epinephrine and, subsequently, to elevate glucose levels in the peripheral blood. The NO system thus seems to be involved in the neural regulation of the adrenal by the GNS, which in turn regulates peripheral blood glucose levels.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002490 Central Nervous System The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges. Cerebrospinal Axis,Axi, Cerebrospinal,Axis, Cerebrospinal,Central Nervous Systems,Cerebrospinal Axi,Nervous System, Central,Nervous Systems, Central,Systems, Central Nervous
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000315 Adrenalectomy Excision of one or both adrenal glands. (From Dorland, 28th ed) Adrenalectomies
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic

Related Publications

K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
June 1995, Critical care medicine,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
April 1994, European journal of pharmacology,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
December 1977, Life sciences,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
September 1993, Biochemistry,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
June 1991, Biochemical and biophysical research communications,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
January 2016, PloS one,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
November 1994, Japanese journal of pharmacology,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
November 1998, European journal of neurology,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
January 1993, European journal of pharmacology,
K Uemura, and T Tamagawa, and Y Chen, and N Maeda, and S Yoshioka, and K Itoh, and H Miura, and A Iguchi, and N Hotta
April 1998, Neuroscience,
Copied contents to your clipboard!